Cargando…
Inhibitory Effect of Probenecid on Osteoclast Formation via JNK, ROS and COX-2
Probenecid is a representative drug used in the treatment of gout. A recent study showed that probenecid effectively inhibits oxidative stress in neural cells. In the present study, we investigated whether probenecid can affect osteoclast formation through the inhibition of reactive oxygen species (...
Autores principales: | Cheng, Mi Hyun, Kim, Sung-Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Applied Pharmacology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939694/ https://www.ncbi.nlm.nih.gov/pubmed/31474032 http://dx.doi.org/10.4062/biomolther.2019.047 |
Ejemplares similares
-
Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021) -
Betulin Suppresses Osteoclast Formation via Down-Regulating NFATc1
por: Kim, Kwang-Jin, et al.
Publicado: (2018) -
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020) -
The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation
por: Liu, Fei-Lan, et al.
Publicado: (2017) -
Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers
por: Zhang, Yi-fan, et al.
Publicado: (2016)